Literature DB >> 19199355

Comparative responsiveness of Parkinson's disease scales to change over time.

Anette Schrag1, Annika Spottke, Niall Patrick Quinn, Richard Dodel.   

Abstract

The objective of the study is to examine the comparative responsiveness of outcome measures to assess progression over time in Parkinson's disease (PD). One hundred twenty-eight patients participating in a clinic-based naturalistic study of PD were assessed with the Hoehn and Yahr, UPDRS, MMSE, PDQ-39, PDQL, EQ-5D, and BDI scales at baseline and at 1 year. In addition, 82 patients in a community-based study of patients with PD who had completed self-rated Schwab and England, PDQ-39, EQ-5D, and BDI scales at baseline, were sent the same questionnaires at 1 and 4 years. Responsiveness was assessed using t-tests, standardised effect size, and standardised response mean. In both samples, the Hr-QoL measures were less responsive to change over time than the impairment and disability scales (Hoehn and Yahr, UPDRS, Schwab and England scales). In addition, in the clinic-based sample, Hoehn and Yahr and UPDRS ADL scale ("on") were more responsive to progression over time than UPDRS motor part and ADL part ("off"). Hr-QoL measures are less responsive to change over time than measures of impairment and disability. Although this suggests that these measures are less accurate in detecting subtle changes, it may also indicate that the multifactorial subjective assessment of Hr-QoL adapts to changes over time. Global assessment of overall impairment and disability (which incorporates motor and nonmotor features of PD), however, appeared relatively responsive to change over time in patients in a naturalistic setting. (c) 2009 Movement Disorder Society.

Entities:  

Mesh:

Year:  2009        PMID: 19199355     DOI: 10.1002/mds.22438

Source DB:  PubMed          Journal:  Mov Disord        ISSN: 0885-3185            Impact factor:   10.338


  23 in total

1.  Three-dimensional rodent motion analysis and neurodegenerative disorders.

Authors:  Tasos Karakostas; Simon Hsiang; Heather Boger; Lawrence Middaugh; Ann-Charlotte Granholm
Journal:  J Neurosci Methods       Date:  2013-10-12       Impact factor: 2.390

2.  Responsiveness of the EQ-5D and 8-item Parkinson's Disease Questionnaire (PDQ-8) in a 4-year follow-up study.

Authors:  Nan Luo; Wai-Yee Ng; Puay-Ngoh Lau; Wing-Lok Au; Louis Cs Tan
Journal:  Qual Life Res       Date:  2010-03-04       Impact factor: 4.147

Review 3.  Can The EQ-5D Detect Meaningful Change? A Systematic Review.

Authors:  Nalin Payakachat; Mir M Ali; J Mick Tilford
Journal:  Pharmacoeconomics       Date:  2015-11       Impact factor: 4.981

4.  Dynamics of change in self-reported disability among persons with Parkinson's disease after 2 years of follow-up.

Authors:  Tatjana Gazibara; Darija Kisic-Tepavcevic; Marina Svetel; Aleksandra Tomic; Iva Stankovic; Vladimir Kostic; Tatjana Pekmezovic
Journal:  Neurol Sci       Date:  2017-05-13       Impact factor: 3.307

5.  Impact of community pharmaceutical care on patient health and quality of drug treatment in Parkinson's disease.

Authors:  Sabrina Schröder; Peter Martus; Per Odin; Marion Schaefer
Journal:  Int J Clin Pharm       Date:  2012-07-19

6.  The Unified Parkinson's Disease Rating Scale as a predictor of peak aerobic capacity and ambulatory function.

Authors:  Frederick M Ivey; Leslie I Katzel; John D Sorkin; Richard F Macko; Lisa M Shulman
Journal:  J Rehabil Res Dev       Date:  2012

7.  Insulin-like growth factor-1 and progression of motor symptoms in early, drug-naïve Parkinson's disease.

Authors:  Marina Picillo; Roberto Erro; Gabriella Santangelo; Rosario Pivonello; Katia Longo; Claudia Pivonello; Carmine Vitale; Marianna Amboni; Marcello Moccia; Annamaria Colao; Paolo Barone; Maria Teresa Pellecchia
Journal:  J Neurol       Date:  2013-02-12       Impact factor: 4.849

8.  Rankin scale as a potential measure of global disability in early Parkinson's disease.

Authors:  Tanya Simuni; Sheng T Luo; Kelvin L Chou; Hubert Fernandez; Bo He; Sotirios Parashos
Journal:  J Clin Neurosci       Date:  2013-06-26       Impact factor: 1.961

9.  Declining quality of life in Parkinson disease before and after diagnosis.

Authors:  Natalia Palacios; Xiang Gao; Michael Schwarzschild; Alberto Ascherio
Journal:  J Parkinsons Dis       Date:  2012       Impact factor: 5.568

10.  Identification of distinct blood-based biomarkers in early stage of Parkinson's disease.

Authors:  Yingyan Wu; Qian Yao; Guo-Xin Jiang; Gang Wang; Qi Cheng
Journal:  Neurol Sci       Date:  2019-12-11       Impact factor: 3.307

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.